Calidi Biotherapeutics Inc (CLDI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,992 | -7,225 | -29,216 | -20,987 | -18,963 |
| Depreciation Amortization | 784 | 390 | 1,688 | 1,603 | 1,057 |
| Accounts payable and accrued liabilities | 1,142 | 968 | -6,170 | -7,655 | -1,672 |
| Other Working Capital | 1,140 | 1,917 | -6,242 | -9,230 | -928 |
| Other Operating Activity | 601 | 119 | 12,957 | 14,472 | 12,226 |
| Operating Cash Flow | $-9,325 | $-3,831 | $-26,983 | $-21,797 | $-8,280 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -5 | -5 | -585 | -515 | -443 |
| Other Investing Activity | 0 | 0 | 107 | 72 | 63 |
| Investing Cash Flow | $-5 | $-5 | $-478 | $-443 | $-380 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | 1,250 | 1,250 | 1,250 |
| Debt Issued | 3,000 | 3,000 | 2,000 | 0 | N/A |
| Debt Repayment | -1,545 | -23 | -101 | -53 | -36 |
| Common Stock Issued | 7,648 | N/A | 281 | 281 | 231 |
| Other Financing Activity | -890 | 36 | 25,614 | 30,524 | 8,921 |
| Financing Cash Flow | $8,213 | $3,013 | $29,044 | $32,002 | $10,366 |
| Exchange Rate Effect | 4 | 17 | -6 | 13 | -10 |
| Beginning Cash Position | 2,167 | 2,167 | 590 | 590 | 590 |
| End Cash Position | 1,054 | 1,361 | 2,167 | 10,365 | 2,286 |
| Net Cash Flow | $-1,113 | $-806 | $1,577 | $9,775 | $1,696 |
| Free Cash Flow | |||||
| Operating Cash Flow | -9,325 | -3,831 | -26,983 | -21,797 | -8,280 |
| Capital Expenditure | -5 | -5 | -585 | -515 | -443 |
| Free Cash Flow | -9,330 | -3,836 | -27,568 | -22,312 | -8,723 |